Abstract
242511
Introduction: 18F-labeled radiotracers targeting norepinephrine transporter (NET) have potential applications in diagnosing and assessing several neuroendocrine tumors, especially in pheochromocytoma, paraganglioma, and neuroblastoma. In this study, we proposed a 2-step radiosynthetic method to prepare a novel guanidine-based PET tracer 18F-PhOG via organic photoredox-mediated 18F-deoxyfluorination. The diagnostic potential was evaluated in a pheochromocytoma model (PC-12).
Methods: 18F-PhOG was prepared according to modified procedures in two steps (aryl 18F-fluorination and deprotection) from a readily available precursor. PET imaging studies were performed on the PC-12 xenograft mice (n = 3) with 18F-PhOG
Results: 18F-PhOG was successfully synthesized in 35.4 ± 3.1% (n = 4) radiochemical yield and more than 97 % radiochemical purity. 18F-PhOG showed a high accumulation in the PC-12 tumor implanted in the right flank of Balb/c nude mice. The tumor uptake at 30, 60, 120, and 240 minutes after intravenous administration was 19.67±3.69, 21.05±3.57, 22.20±5.39 and 20.35±2.93. In comparison, uptake into background tissues was low and the muscle tissue uptake at 30, 60, 120, and 240 minutes was 0.41±0.08, 0.37±0.07, 0.28±0.08 and 0.24±0.06. In addition, NET-expressing tissue like brown fat and heart also showed high uptake, which supports the norepinephrine transporter (NET) targeting specificity of the 18F-PhOG. Notably, compared to the clinically used tracer 18F-MFBG, 18F-LMI1195, and other reported tracers, 18F-PhOG showed exceptionally low liver uptake. This will benefit the accurate diagnosis of potential liver metastases. The high uptake ratio of tumor to background will also promote the radiotherapy agents' development after the exchange of the F-18 to I-131 or At-211 on PhOG.
Conclusions: The novel PET radiotracer 18F-PhOG demonstrated favorable biodistribution in pheochromocytoma model. The preliminary PET imaging results suggest the potential usefulness of 18F-PhOG as a diagnostic agent for the of NET–expressing tumors.